DBV Technologies S.A. (NASDAQ: DBVT) Stock Information | RedChip

DBV Technologies S.A. (NASDAQ: DBVT)


$3.1400
-0.1550 ( -0.63% ) 20.9K

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Market Data


Open


$3.1400

Previous close


$3.2950

Volume


20.9K

Market cap


$64.83M

Day range


$3.1400 - $3.2450

52 week range


$2.2045 - $10.7000

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 75 May 07, 2024
8-k 8K-related 19 May 07, 2024
def Proxies and info statements 5 Apr 26, 2024
ars Annual reports 1 Apr 26, 2024
pre Proxies and info statements 5 Apr 08, 2024
4 Insider transactions 1 Mar 11, 2024
8-k 8K-related 19 Mar 08, 2024
10-k Annual reports 141 Mar 07, 2024
8-k 8K-related 17 Mar 07, 2024
4 Insider transactions 1 Feb 08, 2024

Latest News